Abstract
Background: Depression is a risk factor for mild cognitive impairment (MCI) and for the conversion from MCI to Alzheimer's disease (AD). This study investigated regional cerebral glucose metabolism (rCMglc) in older adults with depression and MCI, either with or without amyloidopathy. Methods: We recruited 31 older adults diagnosed with depression and MCI, and 21 older adults with normal cognition (NC). All participants completed demographic questionnaires and were examined with a standardized neuropsychological battery, F-18 fluorodeoxyglucose positron emission tomography (PET), and F-18 florbetaben PET. We classified subjects with depression and MCI into amyloid-β-positive (CDAP; n = 16) and amyloid-β-negative (CDAN; n = 15) groups. Pairwise rCMglc analyses were conducted between all three groups (CDAP vs. NC, CDAN vs. NC, and CDAP vs. CDAN). Results: In comparison with the NC group, the CDAP group showed reduced rCMglc predominantly in temporoparietal regions, whereas the CDAN group showed lower rCMglc in regions of the frontal lobe, in addition to the temporoparietal regions. The CDAN group also showed lower rCMglc in right anterior cingulate and left inferior orbitofrontal regions, in a comparison between the CDAP and CDAN groups. Limitations: The generalizability of the findings is limited because this study has a relatively small number of participants. In addition, this study used cross-sectional design rather than longitudinal design. Conclusions: Our findings may provide a reference to assess the risk of future cognitive deterioration. Consequently, this study is expected to contribute to prevention and early identification of dementia associated with AD.
Original language | English |
---|---|
Pages (from-to) | 30-36 |
Number of pages | 7 |
Journal | Journal of Affective Disorders |
Volume | 239 |
DOIs | |
Publication status | Published - 2018 Oct 15 |
Bibliographical note
Funding Information:This project was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare , Republic of Korea ( HC15C1509 to HG Jeong) and the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT ( NRF-2015R1C1A1A01052172 to HG Jeong). The funding agency had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript. In addition, it had no role in the decision to submit the article for publication.
Funding Information:
This project was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HC15C1509 to HG Jeong) and the Brain Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (NRF-2015R1C1A1A01052172 to HG Jeong). The funding agency had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript. In addition, it had no role in the decision to submit the article for publication.
Publisher Copyright:
© 2018 Elsevier B.V.
Keywords
- Alzheimer's disease
- Amyloid
- Depression
- FDG-PET
- Hypometabolism
- Mild cognitive impairment
ASJC Scopus subject areas
- Clinical Psychology
- Psychiatry and Mental health